Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma
Adenocarcinomas of the esophagus and stomach are a major cause of cancer-related morbidity and mortality worldwide. For patients with advanced disease, first-line chemotherapy with platinum–fluoropyrimidine combinations prolongs survival, but inevitably the disease progresses with a median progressi...
Main Authors: | Hugo Ford, Ioannis Gounaris |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2015-07-01
|
Series: | Therapeutic Advances in Gastroenterology |
Online Access: | https://doi.org/10.1177/1756283X15585468 |
Similar Items
-
Phase 2 trial of neoadjuvant docetaxel, oxaliplatin, and S‐1 for clinical stage III gastric or esophagogastric junction adenocarcinoma
by: Yukinori Kurokawa, et al.
Published: (2023-03-01) -
Immune Checkpoint Inhibitors: Changing the Treatment Landscape in Esophagogastric Adenocarcinoma
by: Emer Lynch, et al.
Published: (2023-01-01) -
Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
by: Nicholas D. James, et al.
Published: (2022-11-01) -
Integrative proteomic characterization of adenocarcinoma of esophagogastric junction
by: Shengli Li, et al.
Published: (2023-02-01) -
Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
by: Wang Wen-Ping, et al.
Published: (2012-01-01)